Autolus Therapeutics (NASDAQ:AUTL) Sets New 12-Month Low – What’s Next?

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price hit a new 52-week low on Monday . The stock traded as low as $1.86 and last traded at $1.88, with a volume of 258277 shares changing hands. The stock had previously closed at $1.95.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a research report on Friday, November 15th. Needham & Company LLC restated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, January 13th. Finally, The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Autolus Therapeutics currently has an average rating of “Buy” and a consensus target price of $10.40.

Autolus Therapeutics Trading Down 2.3 %

The firm has a 50-day moving average price of $2.23 and a 200-day moving average price of $3.18. The company has a market capitalization of $506.90 million, a price-to-earnings ratio of -1.57 and a beta of 2.02.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. boosted its position in shares of Autolus Therapeutics by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock valued at $139,000 after purchasing an additional 14,959 shares in the last quarter. Privium Fund Management B.V. lifted its stake in Autolus Therapeutics by 15.6% during the third quarter. Privium Fund Management B.V. now owns 185,639 shares of the company’s stock valued at $674,000 after purchasing an additional 25,000 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Autolus Therapeutics during the third quarter worth approximately $1,082,000. HealthInvest Partners AB grew its position in Autolus Therapeutics by 95.6% in the third quarter. HealthInvest Partners AB now owns 442,423 shares of the company’s stock worth $1,606,000 after buying an additional 216,278 shares during the last quarter. Finally, FMR LLC increased its holdings in shares of Autolus Therapeutics by 44.6% in the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after buying an additional 5,478,706 shares in the last quarter. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.